IP Verse

Vista Modulators For Diagnosis And Treatment Of Cancer - EP2892558

The patent EP2892558 was granted to Kings College London on Apr 10, 2019. The application was originally filed on Sep 9, 2013 under application number EP13834707A. The patent is currently recorded with a legal status of "Revoked".

EP2892558

KINGS COLLEGE LONDON
Application Number
EP13834707A
Filing Date
Sep 9, 2013
Status
Revoked
Aug 22, 2025
Grant Date
Apr 10, 2019
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

REGIMBEAUJan 10, 2020REGIMBEAU -

Patent Citations (99) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONEP0264166
DESCRIPTIONEP1176195
DESCRIPTIONUS2004110704
DESCRIPTIONUS2006034852
DESCRIPTIONUS2008287358
DESCRIPTIONUS2011027278
DESCRIPTIONUS2012195894
DESCRIPTIONUS4366241
DESCRIPTIONUS4376110
DESCRIPTIONUS4517288
DESCRIPTIONUS4699880
DESCRIPTIONUS4736866
DESCRIPTIONUS4816567
DESCRIPTIONUS4837168
DESCRIPTIONUS4870009
DESCRIPTIONUS4873191
DESCRIPTIONUS4873316
DESCRIPTIONUS4987071
DESCRIPTIONUS5116742
DESCRIPTIONUS5116964
DESCRIPTIONUS5223409
DESCRIPTIONUS5225539
DESCRIPTIONUS5283317
DESCRIPTIONUS5403484
DESCRIPTIONUS5427908
DESCRIPTIONUS5476996
DESCRIPTIONUS5530101
DESCRIPTIONUS5545806
DESCRIPTIONUS5545807
DESCRIPTIONUS5569825
DESCRIPTIONUS5571698
DESCRIPTIONUS5580717
DESCRIPTIONUS5580756
DESCRIPTIONUS5585089
DESCRIPTIONUS5624821
DESCRIPTIONUS5625126
DESCRIPTIONUS5633425
DESCRIPTIONUS5648260
DESCRIPTIONUS5661016
DESCRIPTIONUS5677425
DESCRIPTIONUS5693762
DESCRIPTIONUS5698767
DESCRIPTIONUS5714350
DESCRIPTIONUS5770429
DESCRIPTIONUS5789650
DESCRIPTIONUS5814318
DESCRIPTIONUS5844095
DESCRIPTIONUS5869046
DESCRIPTIONUS5874299
DESCRIPTIONUS5877397
DESCRIPTIONUS5885793
DESCRIPTIONUS5939598
DESCRIPTIONUS5969108
DESCRIPTIONUS6075181
DESCRIPTIONUS6114598
DESCRIPTIONUS6121022
DESCRIPTIONUS6150584
DESCRIPTIONUS6162963
DESCRIPTIONUS6165745
DESCRIPTIONUS6172197
DESCRIPTIONUS6180370
DESCRIPTIONUS6277375
DESCRIPTIONUS6350861
DESCRIPTIONUS6521404
DESCRIPTIONUS6544731
DESCRIPTIONUS6555313
DESCRIPTIONUS6582915
DESCRIPTIONUS6593081
DESCRIPTIONUS6696686
DESCRIPTIONUS8231872
DESCRIPTIONUS8236304
DESCRIPTIONWO0006593
DESCRIPTIONWO0114424
DESCRIPTIONWO0243478
DESCRIPTIONWO03035835
DESCRIPTIONWO2006116181
DESCRIPTIONWO2011120013
DESCRIPTIONWO9203918
DESCRIPTIONWO9312227
DESCRIPTIONWO9410300
DESCRIPTIONWO9425585
DESCRIPTIONWO9429436
DESCRIPTIONWO9707668
DESCRIPTIONWO9707669
DESCRIPTIONWO9713852
DESCRIPTIONWO9728267
DESCRIPTIONWO9824884
DESCRIPTIONWO9945962
DESCRIPTIONWO9954342
INTERNATIONAL-SEARCH-REPORTUS2013177557
OPPOSITIONUS2011027278
OPPOSITIONWO2011120013
OPPOSITIONWO2011120870
OPPOSITIONWO2013192504
OPPOSITIONWO2014039983
SEARCHWO2006116181
SEARCHWO2011120013
SEARCHWO2013192504
SEARCHWO2014190356

Non-Patent Literature (NPL) Citations (17) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- Topalian S L et al, "Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity", CURRENT OPINION IN IMMUNOLOGY., ELSEVIER, OXFORD., GB, GB, (20120401), vol. 24, no. 2, doi:10.1016/j.coi.2011.12.009, ISSN 0952-7915, pages 207 - 212, XP002714810
OPPOSITION- Emmanuel S Antonarakis, "Combining active immunotherapy with immune checkpoint blockade for the treatment of advanced prostate cancer", Asian Journal of Andrology, US, (20120701), vol. 14, no. 4, doi:10.1038/aja.2012.45, ISSN 1008-682X, pages 520 - 521, XP055376095
OPPOSITION- Julie R. Brahmer et al, "Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.", New England Journal of Medicine, US, (20120628), vol. 366, no. 26, doi:10.1056/NEJMoa1200694, ISSN 1533-4406, pages 2455 - 2465, XP002685330
OPPOSITION- M. A. Curran et al, "PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors", Proceedings of the National Academy of Sciences, (20100302), vol. 107, no. 9, doi:10.1073/pnas.0915174107, ISSN 00278424, pages 4275 - 4280, XP055067204
OPPOSITION- P. Yu et al, "Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model", Proceedings of the National Academy of Sciences, (20120417), vol. 109, no. 16, doi:10.1073/pnas.1203479109, ISSN 00278424, pages 6187 - 6192, XP055147800
OPPOSITION- Wang L et al, "VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses.", The Journal of Experimental Medicine, US, (20110314), vol. 208, no. 3, doi:10.1084/jem.20100619, ISSN 0022-1007, pages 577 - 592, XP002738331
OPPOSITION- Li Wang et al, "Immune Checkpoint Protein Vista as a Novel Target for Cancer Immunotherapy", Journal of Immunology, (20120101), vol. 35, no. 9, page 781, XP055673341
OPPOSITION- Mary E. Keir et al, "PD-1 and Its Ligands in Tolerance and Immunity", Annual Review of Immunology, Annual Reviews Inc., (20080401), vol. 26, no. 1, doi:10.1146/annurev.immunol.26.021607.090331, ISSN 0732-0582, pages 677 - 704, XP055099324
OPPOSITION- P. Yu et al, "Simultaneous Blockade of Multiple Immune System Inhibitory Checkpoints Enhances Antitumor Activity Mediated by Interleukin-15 in a Murine Metastatic Colon Carcinoma Model", Clinical Cancer Research, (20101215), vol. 16, no. 24, doi:10.1158/1078-0432.CCR-10-1966, ISSN 10780432, pages 6019 - 6028, XP055123618
OPPOSITION- Dallas B. Flies et al, "Coinhibitory receptor PD-1H preferentially suppresses CD4+ T cell-mediated immunity", Journal of Clinical Investigation, (20140501), vol. 124, no. 5, doi:10.1172/JCI74589, ISSN 00219738, pages 1966 - 1975, XP055139836
OPPOSITION- Ivan Martinez Forero et al, "Workshop on immunotherapy combinations. Society for immunotherapy of cancer annual meeting Bethesda, November 3, 2011", Journal of Translational Medicine, (20120528), vol. 10, no. 1, doi:10.1186/1479-5876-10-108, ISSN 1479-5876, page 108, XP021126767
OPPOSITION- Benjamin J.C. Quah, Et Al, "The use of carboxyfluorescein diacetate succinimidyl ester (CFSE) to monitor lymphocyte proliferation", J Vis Exp, (20101012), vol. 12, no. 44, doi:10.3791/2259, page 2259, XP055673316
OPPOSITION- PILON-THOMAS SHARI ET AL, "Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma.", The journal of immunology, US, (20100401), vol. 184, no. 7, doi:10.4049/jimmunol.0904114, ISSN 1550-6606, pages 3442 - 3449, XP002767914
OPPOSITION- D. B. Flies et al, "Cutting Edge: A Monoclonal Antibody Specific for the Programmed Death-1 Homolog Prevents Graft-versus-Host Disease in Mouse Models", The Journal of Immunology, (20110815), vol. 187, no. 4, doi:10.4049/jimmunol.1100660, ISSN 00221767, pages 1537 - 1541, XP055140738
OPPOSITION- Zitvogel L. et al, "Targeting PD-1/PD-L1 interactions for cancer immunotherapy", ONCOIMMUNOLOGY, US, (20121101), vol. 1, no. 8, doi:10.4161/onci.21335, ISSN 2162-402X, pages 1223 - 1225, XP002716013
SEARCH[ ] - YUWEN ZHU ET AL, "B7-H5 costimulates human T cells via CD28H", NATURE COMMUNICATIONS, (20130619), vol. 4, doi:10.1038/ncomms3043, XP055139761 [ ] * the whole document *
SEARCH- Peter S Linsley ET AL, "The clinical utility of inhibiting CD28-mediated costimulation", (20090101), URL: http://onlinelibrary.wiley.com/store/10.1111/j.1600-065X.2009.00780.x/asset/j.1600-065X.2009.00780.x.pdf?v=1&t=hzz9hdjq&s=f3d86b43c509c14434935fdf78989229d3a4c150, (20140912), XP055139830 [A] 1-11 * the whole document *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents